Form 4: Adaptive Biotechnologies Director Sells Shares

Adaptive Biotechnologies Director Michelle Griffin exercised options and subsequently sold 48,044 shares of common stock under a pre-arranged 10b5-1 trading plan.

Summary

• Michelle Renee Griffin, a Director at Adaptive Biotechnologies Corporation (ADPT), executed transactions on March 3, 2026.
• Exercised options to acquire 48,044 shares of common stock at an exercise price of $3.99 per share.
• Immediately after the exercise, sold 48,044 shares of common stock at a weighted average price of $15.30 per share.
• The sales occurred within a price range of $15.11 to $15.54 per share.
• These transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on November 7, 2025.
• Following these transactions, Michelle Griffin beneficially owns 15,394 shares of common stock.
• The exercised option was fully vested and exercisable, with an expiration date of March 3, 2034.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a routine insider transaction under a pre-arranged 10b5-1 plan, reflecting a director's planned liquidity event rather than a significant change in sentiment towards the company's future prospects.

Positives

• Director Michelle Griffin realized a significant profit by exercising options at $3.99 and selling shares at an average of $15.30.
• The exercise of options indicates the director is realizing value from previously granted equity compensation.

Negatives

• The sale of 48,044 shares by a director reduces insider ownership, which some investors may view as a negative signal, despite being pre-planned.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider transactions, particularly those executed under Rule 10b5-1 plans, are common occurrences in publicly traded companies. These plans allow insiders to sell shares at predetermined times to avoid accusations of trading on material non-public information, providing a structured approach to liquidity management for executives and directors.

Stakeholder Impact

• Shareholders: May perceive a slight negative signal from insider selling, though mitigated by the 10b5-1 plan.
• Reporting Person (Michelle Griffin): Realized a significant personal gain from exercising options and selling shares.

Key Dates

Recommendation

The transaction is a pre-planned insider sale under a 10b5-1 plan, which typically does not signal a change in the company's fundamental outlook. Investors should consider this a routine liquidity event for the director rather than a strong buy or sell signal for the stock itself. A 'hold' recommendation is appropriate as this filing alone does not provide new information to alter an existing investment thesis.

Keywords

Adaptive Biotechnologies, ADPT, Form 4, Insider Trading, Stock Option Exercise, Share Sale, 10b5-1 Plan, Director Transaction, Equity Compensation